PPT-Clinical Controversies: Recent Updates for Medication Use in Chronic Kidney Disease

Tracy AndersonHaag PharmD BCPS Clinical Pharmacy Specialist Hennepin Healthcare and Clinical Assistant Professor University of Minnesota College of Pharmacy Objectives Describe recent changes to medication labeling guidelines and practice patterns for use of controversial medications in patients with chronic kidney disease. CKD. Dialysis. Renal Transplant. Bones can break, muscles can atrophy, glands can loaf, even the brain can go to sleep without immediate danger to survival. But -- should kidneys fail.... neither bone, muscle, nor brain could carry on.. Kevin Harley, M.D.. Assistant Clinical Professor. Department of Medicine. Division of Nephrology & Hypertension. UC Irvine Medical Center. Objectives. Review Definition of CKD and its classification. Epidemiology. CKD affects about 26 million people in the US. Approximately 19 million adults are in the early stages of the disease . On the rise do to increasing prevalence of diabetes and hypertension. Epidemiology. CKD affects about 26 million people in the US. Approximately 19 million adults are in the early stages of the disease . On the rise do to increasing prevalence of diabetes and hypertension. Chronic Kidney Disease: Detection and Management in Primary Care Julia Scialla, MD, MHS, FASN Associate Professor of Medicine and Public Health Sciences University of Virginia Adjunct Associate Professor of Medicine Chronic Kidney Failure Done by : Resources : Objectives : Extra Book Notes Important Golden Notes Differentiate Chronic kidney disease-CKD from Acute Kidney Injury-AKI. Dr. T. A. L. . Dlamini. Specialist Physician and . Nephrologist. Talk overview . Kidney function. Assessing kidney function. Chronic kidney disease (CKD). Benefits of early detection . Conclusion and take home message . Andrew . Narva. , MD, FASN & . Amy Barton . Pai. , PharmD, MHI, FASN, FCCP, FNKF. Andrew . Narva. , MD, FASN. No financial disclosures/conflicts of interest. Amy Barton . Pai. , PharmD, MHI, FASN, FCCP, FNKF. Namita Singh, MD, FASN. Year 2021. DISCLOSURES. I have no financial relationships with commercial interests to disclose.. This presentation does not include discussion of off-label or investigational use. . Chronic . c. are . Training . For . district . hospital . Nurses . in . Rwanda . 2013. Session 1: Defining chronic kidney disease. By the end of this Session, participants will be able to:. Screen for chronic kidney disease. . Structural . or functional abnormalities of the kidneys for . >. 3 months. . from early to late-stage disease, . Chronic Kidney Disease. as . manifested by either:. 1. Kidney . damage, with or without decreased GFR, as . Quality Department Guidelines for Clinical Care Ambulatory Chronic Kidney Disease Guideline Team Team Leader Jennifer Reilly Lukela, MD General MedicineTeam MembersR. Van Harrison, PhDMedical Educati IntroductionFabry disease (FD) arises from an X-linked defect in lipid storage, whereby deicient or -galactosidase A (-gal A) activity leads to systemic deposition of glyco-sphingolipids, mainly ADAPTED FROM:. . The 2023 Scientific Statement From the AHA:. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic Syndrome. Definition of . Cardiovascular-Kidney-Metabolic Syndrome (CKM).